Market revenue in 2020 | USD 241.7 million |
Market revenue in 2028 | USD 636.4 million |
Growth rate | 12.9% (CAGR from 2020 to 2028) |
Largest segment | Reagent-based |
Fastest growing segment | Reagent-based |
Historical data | 2018 - 2019 |
Base year | 2020 |
Forecast period | 2021 - 2028 |
Quantitative units | Revenue in USD million |
Market segmentation | Reagent-based, Physical Disruption |
Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, Bio-Rad Laboratories Inc, Roche Holding AG ADR, Qiagen NV, Danaher Corp, Miltenyi Biotec, IDEX Corp, BD, Claremont BioSolutions, Parr Instrument Company, Covaris, Cell Signaling Technology, Qsonica |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell lysis and disruption market will help companies and investors design strategic landscapes.
Reagent-based was the largest segment with a revenue share of 62.14% in 2020. Horizon Databook has segmented the China cell lysis and disruption market based on reagent-based, physical disruption covering the revenue growth of each sub-segment from 2018 to 2028.
Precision Medicine Initiative (PMI) launched in 2016 by China that would spend about USD 9.2 billion over the span of 15 years. This initiative is expected to boost the countries healthcare sector, especially precision medicine. Personalized medicine requires robust and rapid processing of tissue samples.
Thefore, a high-throughput platform is required for analysis and sample preparation. For instance, an integrated platform of a solvent extraction protocol with bead-based homogenizer is ideal for quick, reproducible extraction of tissue metabolites.
Moreover, China is expected to play a major role in advancements of cutting-edge precision medicine globally. For this, the country is focused on advancements in the field of population genomics, clinical diagnostics, drug discovery, and personal wellness.
Horizon Databook provides a detailed overview of country-level data and insights on the China cell lysis and disruption market , including forecasts for subscribers. This country databook contains high-level insights into China cell lysis and disruption market from 2018 to 2028, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account